Osivax, a French biopharma developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, has named Nicola Groth its new chief medical officer (CMO).
She brings more than 25 years of experience in vaccine development and has considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments.
"Nicola’s experience in managing late-stage clinical trials and building registration packages for influenza vaccines will be crucial"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze